{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:10:56Z","timestamp":1792174256231,"version":"4.4.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.radonc.2022.07.003","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T23:56:31Z","timestamp":1657324591000},"page":"59-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["HYPORT adjuvant acute toxicity and patient dosimetry quality assurance results \u2013 Interim analysis"],"prefix":"10.1016","volume":"174","author":[{"given":"Santam","family":"Chakraborty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjoy","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selvamani","family":"Backianathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punita","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhash","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosina","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shagun","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Balakrishan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subecha","family":"Bhushal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debashree","family":"Guha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.J.","family":"Maria Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurupa","family":"Mahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abha","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Finlay Godson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abha","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Shamsudden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dinesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debdeep","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2022.07.003_b0005","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1200\/GO.20.00122","article-title":"Cancer statistics, 2020: report from national cancer registry programme","author":"Mathur","year":"2020","journal-title":"India JCO Glob Oncol"},{"key":"10.1016\/j.radonc.2022.07.003_b0010","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.radonc.2022.07.003_b0015","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(14)60488-8","article-title":"Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials","volume":"383","author":"EBCTCG (Early Breast Cancer Trialists' Collaborative Group)","year":"2014","journal-title":"The Lancet"},{"key":"10.1016\/j.radonc.2022.07.003_b0020","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/S0140-6736(11)61629-2","article-title":"Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials","volume":"378","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2022.07.003_b0025","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/S0140-6736(05)67887-7","article-title":"Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials","volume":"366","author":"Clarke","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2022.07.003_b0030","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.clon.2015.04.034","article-title":"Examining determinants of radiotherapy access: do cost and radiotherapy inconvenience affect uptake of breast-conserving treatment for early breast cancer?","volume":"27","author":"Lam","year":"2015","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2022.07.003_b0035","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.clon.2022.03.001","article-title":"From 25 fractions to five: how hypofractionation has revolutionised adjuvant breast radiotherapy","volume":"34","author":"Yarnold","year":"2022","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2022.07.003_b0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.radonc.2005.01.005","article-title":"Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial","volume":"75","author":"Yarnold","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.07.003_b0045","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1470-2045(08)70077-9","article-title":"The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial","volume":"9","author":"START Trialists\u2019 Group","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2022.07.003_b0050","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.radonc.2011.06.026","article-title":"First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE\/04\/015)","volume":"100","author":"FAST Trialists group","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.07.003_b0055","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","article-title":"The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials","volume":"14","author":"Haviland","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2022.07.003_b0060","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/S0140-6736(20)30932-6","article-title":"Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial","volume":"395","author":"Murray Brunt","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2022.07.003_b0065","unstructured":"Postoperative radiotherapy for breast cancer: hypofractionation RCR consensus statements [Internet]. [cited 2022 May 30]. Available from: https:\/\/www.rcr.ac.uk\/publication\/postoperative-radiotherapy-breast-cancer-hypofractionation-rcr-consensus-statements."},{"key":"10.1016\/j.radonc.2022.07.003_b0070","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/j.clon.2020.09.006","article-title":"Can the FAST-forward trial results be generalised across all breast cancer patients?","volume":"33","author":"Chatterjee","year":"2021","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2022.07.003_b0075","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00066-020-01744-3","article-title":"Moderate hypofractionation remains the standard of care for whole-breast radiotherapy in breast cancer: considerations regarding FAST and FAST-forward","volume":"197","author":"Krug","year":"2021","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2022.07.003_b0080","unstructured":"Wheatley D, Haviland J, Patel J, Sydenham M, Alhasso A, Chan C, et al. First results of FAST-Forward phase 3 RCT nodal substudy: 3-year normal tissue effects. In: ESTRO 2022 [Internet]. ESTRO; [cited 2022 May 30]. Available from: https:\/\/www.estro.org\/Congresses\/ESTRO-2022\/547\/late-breaking\/5156\/firstresultsoffast-forwardphase3rctnodalsubstudy-3."},{"key":"10.1016\/j.radonc.2022.07.003_b0085","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.radonc.2013.09.024","article-title":"The Cambridge post-mastectomy radiotherapy (C-PMRT) index: a practical tool for patient selection","volume":"110","author":"Mukesh","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.07.003_b0090","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1186\/s13063-020-04751-y","volume":"21","author":"Chatterjee","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.radonc.2022.07.003_b0095","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000453607","article-title":"Is the deep inspiration breath-hold technique superior to the free breathing technique in cardiac and lung sparing while treating both left-sided post-mastectomy chest wall and supraclavicular regions?","volume":"10","author":"Darapu","year":"2017","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.radonc.2022.07.003_b0100","doi-asserted-by":"crossref","unstructured":"Chakraborty S, Chatterjee S, Moses A, Nallathambi C, Ahmed R. Can Deep Inspiration Breath Hold Radiation Therapy (DIBH) for breast cancers be cost effective in developing nations? In: 2018. p. e400\u20131.","DOI":"10.1016\/j.ijrobp.2018.07.1182"},{"key":"10.1016\/j.radonc.2022.07.003_b0105","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.clon.2018.12.004","article-title":"Simultaneous integrated boost: improving the patient journey during breast cancer radiotherapy safely","volume":"31","author":"Chatterjee","year":"2019","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2022.07.003_b0110","doi-asserted-by":"crossref","first-page":"20120643","DOI":"10.1259\/bjr.20120643","article-title":"Visualisation of the left anterior descending coronary artery on CT images used for breast radiotherapy planning","volume":"86","author":"Vennarini","year":"2013","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2022.07.003_b0115","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ijrobp.2013.08.004","article-title":"An anatomically validated brachial plexus contouring method for intensity modulated radiation therapy planning","volume":"87","author":"Van de Velde","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.07.003_b0120","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/j.clon.2016.05.008","article-title":"Outcomes following a moderately hypofractionated adjuvant radiation (START B type) schedule for breast cancer in an unscreened non-caucasian population","volume":"28","author":"Chatterjee","year":"2016","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2022.07.003_b0125","doi-asserted-by":"crossref","unstructured":"Chatterjee S, Chakraborty S, Das S, Tamil Selvan S, Shrimali RK, Achari R, et al. EP-1198: Cavity Boost (CB) following Fractionated External Beam Radiotherapy (EBRT): time to move on from clinical mark-ups? In: Elsevier BV; 2014. p. S54\u20135.","DOI":"10.1016\/S0167-8140(15)31316-5"},{"key":"10.1016\/j.radonc.2022.07.003_b0130","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.7314\/APJCP.2014.15.6.2505","article-title":"Hypofractionated radiotherapy for breast cancers\u2013preliminary results from a tertiary care center in eastern India","volume":"15","author":"Nandi","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.radonc.2022.07.003_b0135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.radonc.2014.11.030","article-title":"ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer","volume":"114","author":"Offersen","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.07.003_b0140","doi-asserted-by":"crossref","first-page":"S405","DOI":"10.1016\/S0167-8140(15)33369-7","article-title":"EP-1063: Helical Tomotherapy vs. 3dCRT in adjuvant radiotherapy of breast cancer: comparative dosimetry","volume":"106","author":"Nandi","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.07.003_b0145","doi-asserted-by":"crossref","first-page":"543","DOI":"10.4103\/2278-0513.159788","article-title":"Helical tomotherapy based intensity modulated radiotherapy for the management of difficult clinical situations in breast cancer","volume":"4","author":"Saha","year":"2015","journal-title":"Clin Cancer Investig J"},{"key":"10.1016\/j.radonc.2022.07.003_b0150","unstructured":"Coles CE, Griffin CL, Kirby AM, Haviland JS, Titley JC, Benstead K, et al. Dose escalated simultaneous integrated boost radiotherapy for women treated by breast conservation surgery for early breast cancer: 3-year adverse effects in the IMPORT HIGH trial (CRUK\/06\/003) [Internet]. In: San Antonio breast cancer symposium; 2018 Dec 6 [cited 2018 Nov 30]; San Antionio, Texas, USA. Available from: https:\/\/www.abstracts2view.com\/sabcs18\/view.php?nu=SABCS18L_527&terms=."},{"key":"10.1016\/j.radonc.2022.07.003_b0155","article-title":"Adjuvant radiation therapy in breast cancer: recent advances & Indian data","author":"Chakraborty","year":"2022","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.radonc.2022.07.003_b0160","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"key":"10.1016\/j.radonc.2022.07.003_b0165","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1016\/S0167-8140(21)01003-3","article-title":"PO-0985: Hypofractionated radiotherapy with SIB in advanced incurable breast cancer-HYPORT B study","volume":"152","author":"Santosham","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.07.003_b0170","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13014-018-1052-8","article-title":"Cardiac sparing characteristics of internal mammary chain radiotherapy using deep inspiration breath hold for left-sided breast cancer","volume":"13","author":"Nguyen","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2022.07.003_b0175","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0959-8049(01)00440-3","article-title":"EORTC Radiotherapy Group: achievements and future projects","volume":"1","author":"Budach","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2022.07.003_b0180","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.radonc.2012.09.011","article-title":"Compliance with therapeutic guidelines in Radiation Therapy Oncology Group prospective gastrointestinal clinical trials","volume":"105","author":"Willett","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.07.003_b0185","first-page":"40","article-title":"Initial experience with quality assurance of multi-institutional 3D radiotherapy clinical trials. A brief report","volume":"174","author":"Purdy","year":"1998","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2022.07.003_b0190","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1046\/j.1440-1673.1999.00639.x","article-title":"Quality assurance audit in an Australasian phase III trial of accelerated radiotherapy for head and neck cancer (TROG 91.01). Trans-Tasman Radiation Oncology Group","volume":"43","author":"Hamilton","year":"1999","journal-title":"Australas Radiol"},{"key":"10.1016\/j.radonc.2022.07.003_b0195","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.radonc.2016.02.027","article-title":"Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial","volume":"120","author":"Brunt","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.07.003_b0200","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S1470-2045(18)30813-1","article-title":"Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial","volume":"20","author":"Wang","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2022.07.003_b0205","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.radonc.2016.12.023","article-title":"Does an integrated boost increase acute toxicity in prone hypofractionated breast irradiation? A randomized controlled trial","volume":"122","author":"Paelinck","year":"2017","journal-title":"Radiother Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814022041895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814022041895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:22:10Z","timestamp":1759123330000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814022041895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":41,"alternative-id":["S0167814022041895"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2022.07.003","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HYPORT adjuvant acute toxicity and patient dosimetry quality assurance results \u2013 Interim analysis","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2022.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}